| Company Name: |
JINAN SHENGQI PHARMACEUTICAL CO., LTD
|
| Tel: |
0531-88892685 18660160628 |
| Email: |
15069007290@163.com |
| Products Intro: |
Product Name:Revumenib Citrate
CAS:2761046-45-9
Purity:99 Package:1KG;100KG
|
| Company Name: |
Aktin Chemicals, Inc.
|
| Tel: |
028-85159085 |
| Email: |
info@aktinchem.com |
| Products Intro: |
Product Name:Revumenib citrate
CAS:2761046-45-9
Purity:98% Package:100g;500g;1kg;5kg;25kg;可按照客户要求定制包装
|
|
| | Revumenib Citrate Basic information |
| Product Name: | Revumenib Citrate | | Synonyms: | Revumenib Citrate;RMA-745;Revumenib citrate hydrate,2761046-45-9,,Pharmaceutical Chemicals | | CAS: | 2761046-45-9 | | MF: | C32H47FN6O4S.C6H8O7.H2O | | MW: | 840.96 | | EINECS: | | | Product Categories: | | | Mol File: | 2761046-45-9.mol |  |
| | Revumenib Citrate Chemical Properties |
| InChIKey | UBXFWTFPYATLBT-SGBGZXBGNA-N | | SMILES | C([C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)N1CCC2(CC1)CN(C1=NC=NC=C1OC1C=CC(=CC=1C(=O)N(CC)C(C)C)F)C2.C(O)(C(=O)O)(CC(=O)O)CC(=O)O.O |&1:1,4,r| |
| | Revumenib Citrate Usage And Synthesis |
| Description | Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations. Revumenib Citrate is a common salt of Revumenib. |
| | Revumenib Citrate Preparation Products And Raw materials |
|